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Abstract
We report on two adult patients with hepatitis C virus-positive antineutrophil cytoplasmic antibody-
related glomerulonephritis. These patients had a renal-limited form of crescentic glomerulonephritis
with high levels of serum hepatitis C virus RNA. We investigated the efficiency and transition of the
serum levels of creatinine, hepatitis C virus RNA, and hepatic enzymes during corticosteroid therapy
in the two patients. Corticosteroid therapy consisted of intravenous high-dose methylprednisolone
for 3 days, followed by oral prednisolone without cyclophosphamide. During this course of treatment,
renal function in both patients recovered remarkably. A marked increase in the level of hepatitis C
virus RNA, however, was observed with or without an increase in serum levels of hepatic enzymes.
It seems that steroid therapy for patients who have antineutrophil cytoplasmic antibody-related
pauci-immune crescentic glomerulonephritis and high levels of hepatitis C virus RNA is efficient
and relatively safe, although serum levels of hepatitis C virus RNA and liver function need to be
carefully monitored.
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INTRODUCTION
Antineutrophil cytoplasmic antibody (ANCA) in sera is
frequently detected in patients with pauci-immune
crescentic glomerulonephritis. These patients usually
demonstrate clinical findings of rapidly progressive
glomerulonephritis. Hepatitis C virus (HCV)-related
nephropathy, however, usually presents as membra-
noproliferative glomerulonephritis with glomer-
ular immunoglobulin deposition and/or the pres-
ence of hypocomplementemia and cryoglobulinemia.
Performing a renal biopsy at the early stage of both
diseases is useful to determine the optimum design of
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ANCA-associated glomerulonephritis with HCV-RNA
treatments such as steroids, immunosuppressive agents,
anticoagulants, interferon, and plasmapheresis. We report
on two patients with myeloperoxidase (MPO)-ANCA-
positive pauci-immune crescentic glomerulonephritis
with high levels of serum HCV-RNA, who received
corticosteroid therapy without cyclophosphamide.
CASE REPORTS
Case 1
A 65-year-old woman was admitted to the Juntendo
University Hospital at August 17, 1996 because of edema
in the lower extremities. She had previously visited a
local clinic, where the following laboratory tests results
were obtained: serum creatinine, 282.88 µmol/L (normal
range, 50-110 µmol/L); serum urea nitrogen, 22.9 mmol/
L (normal range, 3-6.5 mmol/L); white blood cell count,
3.4 x 109/L (normal range, 3.2-9.8 x 10a/L); hemoglobin,
62 g/L (normal range, 115-155 g/L); and platelet count,
73 x 109/L (normal range, 150-450 ( 109/L). No patient
of family history of renal disease was found. She had
undergone accouchement with a blood transfusion when
she was aged 27 years. Hypertension had been managed
with calcium antagonist since 56 years of age. The level
of hepatic enzymes at the time of admission (aspartate
aminotransferase 66 U/L [normal range, 0-35 U/L],
alanine aminotransferase 42 U/L [normal range, 0-35
U/L]) was slightly increased. During the observation
period, no abnormality in the urinalysis was observed.
Physical examination showed the following results:
height, 153 cm; weight, 48 kg; boby temperature, 36.7oC;
respiration rate, 18 breaths per minute; heart rate, 94 beats
per minute; and blood pressure, 186/100 mm Hg. Mild
anemia and pretibial edema were observed. No jaundice,
hepatomegaly, ascites, or lymphoadenopathy was
detected. Laboratory test results were as follows: white
blood cell count, 4.3 x 109/L; eosinophil count, 60.2 x
106/L; red blood cell count, 2 x 1012/L (normal range,
3.5-5 x 1012/L); hemoglobin, 67 g/L; hematocrit, 20.5%;
and platelet count, 138 x 109/L. The bleeding time was 3
minutes; activated partial thromboplastin time, 36
seconds; and prothrombin time, 9.6 seconds. The serum
creatinine level was 274.04 µmol/L; serum urea nitrogen,
19.3 mmol/L; proteinuria, 2+; urinary occult blood, 3+;
fasting plasma glucose, 5.4 mmol/L (normal range, 3.9-
6.1 mmol/L); total serum protein, 64 g/L (normal range,
60-80 g/L); serum albumin, 34 g/L (normal range, 40-
60 g/L), and total plasma cholesterol, 3.96 mmol/L
(normal value, <6.85 mmol/L). The level of C-reactive
protein was 3 mg/L; antinuclear antibody, x160;
rheumatoid factor, 20 IU/mL; and 50% of hemolytic unit
of complement (CH50), 38.4 U. Reactivity of HCV
antibody was positive, but hepatitis B virus antigen was
absent. Hepatic enzyme levels were slightly higher, as
shown in Table 1. Urinary protein excretion was 4 g/d.
Urinary sediments contained 11 to 15 red blood cells
per high-power field (HPF), white blood cells 1 to 5 per
HPF, and 1+ red and white blood cell casts. Creatinine
clearance was 0.16 mL/s (normal range, 1.28-2.08 mL/s).
A chest x-ray showed no abnormality. Abdominal
echography indicated mild splenomegaly without
hepatomegaly and ascites. A serological test for MPO-
ANCA showed 831 Eu (normal range, <10 Eu), although
tests for cytoplasmic PR3-ANCA and antiglomerular
basement membrane antibodies gave negative results.
The serum HCV-RNA concentration was 0.5 mEq/mL.
Light microscopy revealed necrotizing glomerulo-
nephritis with crescents in more than 75% of up to 20
glomeruli per level section (Fig. 1). Segmental fibrinoid
necrosis and neutrophil infiltration in glomeruli were also
observed. Mononuclear leukocytes infiltrated into the
interstitium. Tubular atrophy and interstitial fibrosis were
Table 1. Laboratory data at admission to the Juntendo University Hospital.
Case 1 Case 2
Serum creatinine (µmol/L) 274.04 425.20
Serum urea nitrogen (mmol/L) 19.3 19.6
Creatinine clearance (mL/s) 0.18 0.27
Urinary protein (g/d) 4.0 1.9
Total serum protein (g/L) 64 84
Serum albumin (g/L) 34 38
Immunoglobulin G (mg/dL) 1936 3487
MPO-ANCA (Eu) 831 84
Rheumatoid factor (IU/mL) 20 108
CH50 (U) 38.4 38.9
Antinuclear antibody (x) x160 x40
Hepatitis C virus-RNA (mEq/mL) <0.5 1.1
Aspartate aminotransferase (U/L) 66 11
Alanine aminotransferase (U/L) 42 11
CH50  = 50% of hemolytic unit of complement; MPO-ANCA = myeloperoxidase antineutrophil cytoplasmic antiboby
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observed. Immunofluorescence demonstrated no staining
of immunoglobulin (Ig) G, IgA, IgM, and complement
proteins C3, and C1q. Electron microscopy demonstrated
segmental sclerosis, fibrocellular crescents, matrix
expansion, and epithelial cell atrophy without electron-
dense deposits in the glomeruli. The histological
diagnosis was MPO-ANCA-related crescentic
glomerulonephritis without HCV-related nephropathy.
Methylprednisolone 500 mg/d was given for 3 days,
followed by oral administration of prednisolone. The
level of serum creatinine reached 371.28 µmol/L after
20 days of corticosteroid (prednisolone) treatment
and then decreased to 150.28 µmol/L within the next
11 weeks. Serum HCV-RNA levels were markedly
increased, to 4 mEq/mL, although hepatic enzyme levels
and echographic features of the liver after the admin-
istration of corticosteroid were unchanged.
Case 2
A 59-year-old man was presented to the Department of
Internal Medicine of the Juntendo University Hospital
at August 19, 1996 because of general fatigue. Increased
proteinuria (1.9 g/d) and renal insufficiency were found
in a routine medical checkup. Slight proteinuria had
Figure 1. Photomicrograph of glomerulus showing crescentic
formation in Case 1 (periodic acid-Schiff stain x400).
Figure 2. Photomicrograph of glomerulus showing crescentic
formation in Case 2 (periodic acid-Schiff stain x400).
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ANCA-associated glomerulonephritis with HCV-RNA
been found 2 years previously during a health screen.
Laboratory tests at admission to hospital showed serum
creatinine of 380.12 µmol/L; serum urea nitrogen, 20.2
mmol/L; white blood cell count, 12.9 x 109/L; hemoglobin,
101 g/L; hematocrit, 31.2%; and platelet count, 278 x
109/L. There was no patient of family history of renal
disease. The patient had undergone gastrectomy with
blood transfusion at the age of 46 years. Hypertension
existed without any treatment from 57 years of age.
Physical examination demonstrated a body height of
166.5 cm, body weight of 58 kg, body temperature of
37.2oC, respiration rate of 14 breaths per minute, heart
rate of 92 beats per minute, and blood pressure of 120/
60 mm Hg. No jaundice, hepatosplenomegaly, ascites,
or edema was present. Laboratory data included the
following: white blood cell count, 10.1 x 109/L;
eosinophil count, 20.2 x 106/L; red blood cell count, 3.5
x 1012/L (normal range, 4.3-5.9 x 1012/L); hemoglobin,
104 g/L; hematocrit, 31.4%; platelet count, 280 x 109/L;
serum creatinine, 425.2 µmol/L; serum urea nitrogen,
19.6 mmol/L; and urinary protein, 1.9 g/d. Urinary
sediments contained 26 to 30 red blood cells per HPF,
26 to 30 white blood cell per HPF, and 1+ red and white
blood cell casts. Creatinine clearance was 0.2 mL/s;
fasting plasma glucose, 5.7 mmol/L; total serum protein,
84 g/L; serum albumin, 38 g/L; and total cholesterol,
4.91 mmol/L. The C-reactive protein level was 3 mg/L,
antinuclear antibody x40, rheumatoid factor 108 IU/mL,
and CH50 38.9 U. Although HCV antibody was present,
hepatic enzyme levels were not increased. A chest
x-ray and abdominal echography did not show any
abnormality. A serological test for MPO-ANCA
was 84 Eu, although cytoplasmic PR3-ANCA and
antiglomerular basement membrane antibody were both
absent. Serum HCV-RNA was 1.1 mEq/mL (Table 1).
Light microscopy showed evidence of necrotizing
glomerulonephritis, with crescents in more than 90% of
up to 18 glomeruli per level section (Fig. 2). Segmental
fibrinoid necrosis and neutrophil infiltration were also
observed in the glomeruli. Mononuclear leukocyte
infiltration was observed in the interstitium but not in
the perivascular areas. Tubular atrophy and interstitial
fibrosis were observed. No staining of IgG, IgA, IgM,
C3 and C1q was observed by immunofluorescence
microscopy. Electron microscopy demonstrated seg-
mental collapse, fibrocellular crescents, and epithelial
cell atrophy without dense deposits. The histological
diagnosis was MPO-ANCA-related crescentic
glomerulonephritis without HCV-related nephropathy.
The patient was treated with intravenous methyl-
prednisolone 200 mg/d for 3 days, then with oral
prednisolone. The reasons for low-dose steroid therapy
were concerns of increased HCV-RNA levels and
progression of renal fibrosis. The level of serum
creatinine peaked at 495.04 µmol/L before steroid therapy
and then decreased to 247.52 µmol/L after 8 weeks of
steroid therapy. The serum HCV-RNA concentration
increased to 32 mEq/mL, but hepatic enzyme levels and
echographic features of the liver were stable. The clinical
courses of both patients are shown in Figure 3.
DISCUSSION
The two patients in this case report had HCV-positive
ANCA-related glomerulonephritis. No glomerular
deposition of immunoglobulin, cryoglobulinemia, or
hypocomplementemia was found. The two patients also
did not show any pathology of HCV-related nephropathy.
Because approximately 1.5% of Japanese have anti-HCV
antibodies (Ohkura, personal communication), the
frequency of ANCA-related and HCV-unrelated
glomerulonephritis with HCV seemed to be rare.
Most patients with pauci-immune crescentic glo-
merulonephritis show evidence of systemic micro-
vasculitis (1,2). Because these two patients had not
demonstrated any sign of systemic vasculitis, the
diagnosis was defined as a renal-limited form of
crescentic glomerulonephritis with high levels of serum
HCV-RNA. Given the fact that the prognosis of pauci-
immune rapidly progressive glomerulonephritis is poor,
aggressive treatment such as steroid pulse therapy
combined with cyclophosphamide is usually used,
although prospective studies have not been reported (3).
Nachman et al (4) reported that treatment with pre-
dnisolone results in only a three-fold increased risk of
relapse when compared with treatment with cyclo-
phosphamide. Quint et al (5) reported that combination
therapy with corticosteroid, vidarabine, and plasma
exchange is effective for patients who have polyarteritis
and who are positive for anti-HCV antibody. Leuko-
cytopenia and carcinogenicity, however, are important
side-effects of cyclophosphamide therapy in HCV-
positive patients, but these two patients showed no
evidence of systemic angiitis. Thus, we chose the steroid
pulse therapy without cyclophosphamide and interferon.
However, Ohta et al (6) reported that inter-feron therapy
for HCV may exacerbate the underlying glomerulopathies,
even for unrelated HCV.
The two patients in this case report were given
intravenous high-dose methylprednisolone for 3 days
followed by daily oral prednisolone without cyclo-
phosphamide therapy. Levels of HCV-RNA in the serum
increased from 15 days after initial steroid therapy, and
the level of hepatic enzymes also slightly increased in
the patient in Case 1. We speculate that the increase in
the level of hepatic enzymes in this case was not related
to HCV, because these elevations were not synchronized
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with the copy number of HCV-RNA. In Case 2, the HCV-
RNA level started to increase from 15 days after the
second course of methylprednisolone pulse therapy
without an increase in hepatic enzyme levels. Because
steroid therapy in these patients seemed to be efficient
for the recovery of renal function and reduction of
proteinuria, we avoided additional administration of
cyclophosphamide.
The recovery of renal function and reduction of pro-
teinuria were associated with decreased ANCA titers in
both cases. Titers of ANCA are elevated in 23% to 77%
of patients during relapse (7,8). Falk and Jennette (9)
reported that the titers of ANCA may increase even if
overt clinical relapse has not occurred. In some patients,
ANCA titers are persistently observed during clinical
remission. Some patients, however, have a clinical
relapse that is not associated with any elevation in ANCA
titers (9). Hence, ANCA levels may not always reflect
Figure 3. (A) Clinical course of Case 1. Serum HCV-RNA levels were increased to 4 mEq/
mL, although hepatic enzyme levels were unchanged and serum creatinine levels decreased
to 150.28 µmol/L after 11 weeks of corticosteroid therapy. (B) Clinical course of Case 2.
Serum HCV-RNA levels were markedly increased to 32 mEq/mL, although hepatic enzymes
were unchanged and serum creatinine levels were decreased to 247.52 µmol/L after 8 weeks
of corticosteroid therapy.
ALT = Alanine aminotransferase; AST = Aspartate aminotransferase; BUN = blood urea
nitrogen; CH50 = 50% hemolytic unit of complement; HCV = Hepatitis C virus; MPO-ANCA =
Myeloperoxidase antineutrophil cytoplasmic antiboby; mPSL = methylprednisolone; s-Cr =
serum creatinine
(A)
(B)
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ANCA-associated glomerulonephritis with HCV-RNA
clinical features.
Because of concerns of deterioration of liver function,
we did not choose the additional treatment of cyclo-
phosphamide. Although the long-term prognosis remains
unknown, it seems that treatment with steroid pulse
therapy without cyclophosphamide is valuable for the
renal-limited form of crescentic glomerulonephri-
tis with positive HCV-RNA. In these two patients,
remarkable deterioration of liver function was not
observed, but levels of HCV-RNA were markedly
increased after corticosteroid therapy. Close monitoring
of serum levels of HCV-RNA, ANCA titers, and liver
function during steroid pulse therapy is thus necessary.
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